Hydroxyprogesterone oral - Lipocine

Drug Profile

Hydroxyprogesterone oral - Lipocine

Alternative Names: Hydroxyprogesterone caproate - Lipocine; LPCN-1107; Oral hydroxyprogesterone caproate - Lipocine

Latest Information Update: 17 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lipocine
  • Class Hormones; Pregnenediones; Progesterone congeners; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preterm labour
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Preterm labour

Most Recent Events

  • 06 Mar 2017 Lipocine plans to initiate a phase III trial for Preterm labour (Prevention) in H1 2017
  • 06 Mar 2017 Lipocine announces intention to submit protocol for phase III study to US FDA through Special Protocol Assessment (SPA) for Preterm labour (Prevention) in 1H 2017
  • 06 Mar 2017 Lipocine completed an End-of-phase-II meeting before March 2017 with US FDA to discuss protocol for planned phase III study in Preterm labour
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top